« Back to report listing

OVERVIEW

Cost:$3000

PUBLICATION DATE:August 2010

THERAPEUTIC CLASS:ONCOLOGY

Number of Pages:152

super report icon

US Targeted Therapeutics Comprehensive Analysis

Detailed Pipeline Analysis & Market Forecast 2010-2013

REPORT SUMMARY

The US Targeted Therapeutics Comprehensive Analysis: Detailed Pipeline Analysis & Market Forecast 2010-2013 report provides valuable insights and access to the competitive information influencing the direction of the targeted therapies market from 2010 -2013. This report is saturated with information highlighting the individual products used in each MOA in a detailed pipeline analysis. The report is very thorough and goes one step beyond our Targeted Therapeutics Market Analysis.


EXECUTIVE SUMMARY

Cancer is the second leading cause of death in the United States. Even though there have been many advances in detection and treatment of cancer, the disease is yet to be cured. Cancer is defined as a group of cells that display uncontrolled growth (division beyond the normal limits), invasion (intrusion on and destruction of adjacent tissues), and sometimes metastasis (spread to other locations in the body via lymph or blood). These abnormal cells start invading the nearby healthy cells leading to their destruction which later impacts the functioning of the organ. In advanced stages, cancer cells can migrate to nearby organs or to any organ in the body through blood or lymph system, thereby impacting those organs too. Cancer is often detected when it has reached advanced stages, putting additional pressure on treatment options.

Targeted therapy is a relatively new therapeutic option for treating cancer. It involves the use of either monoclonal antibody or small molecules, which target specific areas of the cancerous cells that are important for cell function. These drugs usually inhibit specific proteins which eventually lead to cell death. The death of the cancer cells is achieved without, or by minimally affecting, the healthy cells.

Targeted Therapeutics Market Analysis

In 2008, the targeted cancer therapeutics market was estimated to be valued at $9.83 billion. This market is forecasted to grow at a healthy growth rate of 14.2 percent over the forecast period, 2008 to 2013. By the end of forecast period, 2013, the targeted therapeutics market is expected to be worth $19.14 billion.

The targeted drugs can be monoclonal antibodies or small molecules. They are further classified on the basis of the target they inhibit. Some of the key segments of targeted therapeutics considered in this study are tyrosine kinase inhibitors, such as epidermal growth factor receptor (EGFR) inhibitors and human epidermal receptor (HER), angiogenesis inhibitor or vascular endothelial growth factor receptor (VEGFR) inhibitor, proteasome inhibitors, immunotherapy, multiple tyrosine kinase inhibitors and mTOR inhibitors. Currently, VEGFR inhibitor is the largest segment in this market and its only drug, Avastin, by Genentech / Roche, is responsible for the whole revenues from this segment. Closely following the footsteps of VEGFR inhibitors is the immunotherapy segment. The sales of this segment are mainly driven by Genentech / Roche’s Rituxan. Multiple tyrosine kinase inhibitors and HER-2 inhibitors follow the immunotherapy agents. The newer classes of targeted therapeutics such as proteasome inhibitors and mTOR inhibitors are yet to make a huge impact on the market. In 2013, the market share and ranking of these classes are likely to change due to increased pipeline potential of multiple tyrosine kinase inhibitors and EGFR inhibitors.


TABLE OF CONTENTS

  • Chapter 1: Introduction to Cancer
    • Types of Cancer
    • Cancer Treatment Options
    • Types of Cancer Based on Site of Occurence
  • Chapter 2: Introduction to Targeted Therapy
    • Classes of Targeted Therapy
      • Tyrosine Kinase Receptor Inhibitors (TKI)
      • Angiogenesis Inhibitors
      • Proteasome Inhibitors
      • Immunotherapy
      • Multiple Tyrosine Kinase Inhibitors
      • mTOR inhibitors
  • Chapter 3: Revenue Analysis
    • Targeted Therapy Market Overview
      • Drivers for the targeted therapeutics market
      • Restraints for the targeted therapeutics market
      • Challenges faced by the targeted therapeutics drugs market
    • Targeted Therapeutics Market Analysis
    • Revenue Analysis by Segment
    • VEGFR inhibitors
    • Immunotherapy
    • EGFR inhibitors
    • HER-2 inhibitors
    • Multiple Tyrosine Kinase Inhibitor
    • mTOR inhibitors
    • Other Classes
  • Chapter 4: Competitive Analysis
    • Product Analysis
    • Market Share Analysis
    • Top 5 targeted drugs according to the revenues generated in the United States
  • Chapter 5: Product Analysis
    • Avastin (bevacizumab)
    • Rituxan
    • Herceptin (trastuzumab)
    • Tarceva (erlotinib)
    • Afinitor (Everolimus)
    • Gleevec (Imatinib)
    • Nexavar (Sorafenib)
    • Erbitux (cetuximab)
    • Sutent (sunitinib)
    • Velcade (bortezomib)
    • Tykerb (lapatanib)
    • Campath (alemtuzumab)
  • Chapter 6: Pipeline Analysis Overview
    • Targeted Therapeutics Market: Approved drugs pipeline, by development phase
  • Chapter 7: Detailed Pipeline Analysis
    • Targeted Therapeutics Pipeline Analysis: By Segment based on Mechanism of Action
      • VEGFR inhibitors (Anti Angiogenesis inhibitors)
      • EGFR Inhibitors
      • HER-2 Inhibitors in Pipeline
      • Multiple Tyrosine Kinase Inhibitors
      • Immunotherapy
      • mTOR Inhibitors
    • Targeted Therapeutics Pipeline Analysis: By Development Phase
    • Targeted Therapeutics Pipeline Analysis: By Company
    • Targeted Therapeutics Pipeline Analysis: By Type of Cancer
  • Chapter 8: Late Phase Analysis of Some Key Pipeline Drugs
    • Axitinib
    • Votrient (Pazopanib)
    • Vectibix (panitumumab)
    • Recentin (cediranib)
    • IMC-1121B (Ramucirumab)
    • IMC-11F8 (necitumumab)
    • ZD4054
    • Tasigna (nilotinib)

COMPANIES DISCUSSED

  • Pfizer
  • Roche/Genentech
  • Novartis
  • Wyeth
  • Genzyme
  • Bristol Myers Squibb
  • Imclone
  • Eli Lilly
  • Biogen Idec
  • Medarex
  • Amgen
  • Bayer
  • Onyx
  • GSK
  • AstraZeneca
  • Takeda
  • Genmab
  • Millennium
  • Merck
  • ARIAD
  • RIT Oncology
  • Spectrum
  • Chephalon
  • Celgene
  • Dr. Reddy's
  • OSI
  • Teva
  • Mylan
  • Johnson and Johnson PRD
  • Janssen-Cilag
  • Regeneron
  • Sanofi Aventis
  • YM BioSciences
  • RIT Oncology

DRUGS DISCUSSED

  • Avastin
  • Alimta
  • Rituxan
  • Tarceva
  • Afinitor
  • Axitinib
  • Aflibercept
  • Bosutinib
  • Bexxar
  • Bravanib
  • Campath
  • Certican
  • Cevarix
  • Erbitux
  • Decatuzumab
  • FOLFOX
  • FOLFIRI
  • Figitumumab
  • GA101
  • Galiximab
  • Getfitinib
  • Gleevec
  • Glivec
  • HSP90 inhibitor
  • Herceptin
  • IMC-1121B
  • IMC-11F8
  • ipilimumab
  • Ixempra
  • Iressa
  • Lumiliximab
  • Lucentis
  • MLN0518
  • Motesanib
  • Neratinib
  • Nexavar
  • Natalizumba
  • Nimotuzumab
  • Ofatumumab
  • Pazopanib
  • Tykerb
  • Pertuzumab
  • Recentin
  • Revlimid
  • Rituxan
  • ridaforolimus
  • Saracatinib
  • Sprycel
  • Sutent
  • Tarceva
  • Tasigna
  • Taxotere
  • Torisel
  • Treanda
  • Tykerb
  • Vectibix
  • Velcade
  • Volociximab
  • Votrient
  • Zactima
  • Zalutumumab
  • Zevalin
  • ZD4054
  • Zometa
  • Zactima
  • Xeloda
  • ZOLADEX
  • CASODEX